Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan Healthgen BiotechnologySHSE:688765 +4.66%19 Days Inventory is 2,175.91 as of Mar. 2026, which is 97% above its 10-year median of 1,106.29. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 923 Drug Manufacturers companies, Wuhan Healthgen Biotechnology ranks worse than 98.81% on this metric.
The historical rank and industry rank for Wuhan Healthgen Biotechnology's Days Inventory or its related term are showing as below:
SHSE:688765'
s Days Inventory Range Over the Past 10 Years
Min: 477.29 Med: 1106.29 Max: 1723.66
Current: 1237.91
During the past 12 years, Wuhan Healthgen Biotechnology's highest Days Inventory was 1723.66. The lowest was 477.29. And the median was 1106.29.
SHSE:688765's Days Inventory is ranked worse than 98.81% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs SHSE:688765: 1237.91
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Wuhan Healthgen Biotechnology's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Wuhan Healthgen Biotechnology's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 13.82.
Wuhan Healthgen Biotechnology (SHSE:688765) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Wuhan Healthgen Biotechnology's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Wuhan Healthgen Biotechnology's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Wuhan Healthgen Biotechnology Days Inventory Related Terms
Wuhan Healthgen Biotechnology Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Healthgen Biotechnology Days Inventory Chart
SHSE:688765 vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Healthgen Biotechnology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Healthgen Biotechnology Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wuhan Healthgen Biotechnology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Wuhan Healthgen Biotechnology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Healthgen Biotechnology (SHSE:688765) has a Days Inventory of 2,175.91 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Wuhan Healthgen Biotechnology and its competitors. This is 97% above median its historical median of 1,106.29. Over the past decade, Wuhan Healthgen Biotechnology's Days Inventory has ranged from 477.29 to 1,723.66. According to the industry distribution chart, Wuhan Healthgen Biotechnology ranks #912 out of 923 companies in the Drug Manufacturers industry, placing it in the top 98.8%.
Is Wuhan Healthgen Biotechnology's Days Inventory too high?
Wuhan Healthgen Biotechnology's current Days Inventory of 2,175.91 is 97% above median its 10-year median of 1,106.29. Over the past 10 years, this metric has ranged from a low of 477.29 to a high of 1,723.66. The Drug Manufacturers industry median Days Inventory is 164.38. Wuhan Healthgen Biotechnology's value of 2,175.91 is 1223.7% above this industry median. Based on the distribution chart, Wuhan Healthgen Biotechnology ranks #912 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wuhan Healthgen Biotechnology ranks #912 out of 923 companies for Days Inventory. This places Wuhan Healthgen Biotechnology in the lower half of its industry. The industry median Days Inventory is 164.38. Wuhan Healthgen Biotechnology's value of 2,175.91 is 1223.7% above this benchmark. Historically, Wuhan Healthgen Biotechnology's own Days Inventory has ranged from 477.29 to 1,723.66 over the past decade. While the company's 10-year median is 1,106.29 vs. the industry median of 164.38, Wuhan Healthgen Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuhan Healthgen Biotechnology's current Days Inventory of 2,175.91 is 1223.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Wuhan Healthgen Biotechnology and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Healthgen Biotechnology's current Days Inventory is 2,175.91, which is 97% above median its own 10-year median of 1,106.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Days Inventory of 2,175.91. The current Days Inventory is 2,175.91, which is 97% above median its 10-year median of 1,106.29 and 1223.7% above the Drug Manufacturers industry median of 164.38. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Days Inventory is 2,175.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan Healthgen Biotechnology Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688765 has been successfully added to your 
